BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
$76.18 -0.5 (-0.6521%)
Analysed BRIDGEBIO PHARMA INC (BBIO:NASDAQ) News Sources
Four Biotech Stocks Near Buy Points As Earnings Season Kicks In
17-04-2026
yahoo.com
Sector Update: Health Care Stocks Mixed Late Afternoon
09-04-2026
yahoo.com
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus
09-04-2026
yahoo.com
Sector Update: Health Care Stocks Advance in Afternoon Trading
09-04-2026
yahoo.com
BridgeBio Pharma Evolving Into Rare Disease Powerhouse From TTR Roots, RBC Says
09-04-2026
yahoo.com
Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls
09-04-2026
yahoo.com
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why
31-03-2026
yahoo.com
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
30-03-2026
yahoo.com
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
30-03-2026
yahoo.com
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative?
29-03-2026
yahoo.com
What is the current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is $76.18.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is $-0.5.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is -0.6521%.
What is the most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is .
SEC-8K** Filing Available For BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.